PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer
In our study, preliminary evidence provided the anticancer activity and acceptable adverse effects of sintilimab administered every 3 weeks to pretreated patients with mTNBC. Sintilimab showed its efficacy and safety of immunotherapy for patients with advanced TNBC.
Authors
- Zhongsheng Tong (ORCID: https://orcid.org/0000-0003-4569-1311)
- Yehui Shi (ORCID: https://orcid.org/0000-0001-9649-7119)
- Guolei Dong (ORCID: https://orcid.org/0009-0001-1230-8374)
- Yan Jia (ORCID: https://orcid.org/0000-0001-9338-5859)
- Xiaojing Guo (ORCID: https://orcid.org/0000-0003-3753-2900)
- Jing Zhang (ORCID: https://orcid.org/0000-0001-8861-7336)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.3389/fcell.2024.1430310
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- National Natural Science Foundation of China
- Tianjin Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences